Australian shares were flat with a positive bias on Wednesday, amid softer-than-expected US inflation data. The S&P/ASX 200 was little changed to close at 8,820.6. Core US Consumer Price Index rose 0.

SYDNEY--Neuren Pharmaceuticals shares gained after its U.S. partner signaled global net sales of the Daybue treatment for Rett Syndrome could reach US$700 million in 2028. Shares were recently up 8.3% ...

Rett syndrome is a rare developmental disorder, most often due to a mutation in the MECP2 gene on the X chromosome, but it’s not usually inherited. Advances in genetics have launched a new era in ...

New discoveries about the severe developmental disorder known as Rett syndrome could open the door to better treatments for the devastating, life-shortening condition. Scientists investigating the ...

Symptoms and disease progression of Rett syndrome are different in females than males. A new study shows why it is important to understand these differences to develop better treatments. A new UC ...

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that Health Canada has granted marketing authorization of DAYBUE™ (trofinetide) for the treatment of Rett ...

Taysha Gene Therapies, Inc. cohort 2 higher dosing TSHA-102 data from adolescent and adult phase 1/2 REVEAL study treating patients with Rett Syndrome is expected in 2nd half of 2024. Cohort 1 data of ...